​

​

2025

​

2024

​

  ​ ​ ​

$

  ​ ​ ​

$

​

​

(Restated – see Note 4)

​

(Restated – see Note 4)

Research and Development Expenses

​

  ​

Amortization of intangible asset

​

55,795

​

55,795

Preclinical development

​

726,790

​

2,085,692

Chemistry, manufacturing and controls

​

3,391,560

​

1,571,048

Licensing and patent legal fees

​

449,183

​

535,066

Clinical and regulatory

​

2,924,649

​

5,845,332

Salaries and benefits

​

4,356,192

​

3,702,721

Stock-based compensation

​

1,128,814

​

1,003,970

Other research and development

​

433,249

​

705,722

​

​

13,466,234

​

15,505,346

​

​

2025

​

2024

​

  ​ ​ ​

$

  ​ ​ ​

$

​

​

(Restated – see Note 4)

​

(Restated – see Note 4)

General and Administration Expenses

​

  ​

Depreciation expense

​

—

​

28,003

Legal, professional and finance

​

2,236,274

​

831,755

Investor and public relations

​

1,423,329

​

1,238,152

Salaries and benefits

​

2,941,903

​

1,958,369

Stock-based compensation

​

2,474,805

​

3,526,021

Other general and administrative

​

745,413

​

578,770

​

​

9,821,724

​

8,161,070